Sector Expert: Matthew Andrews

Wells Fargo Securities



Recent Quotes

"We believe there is ample precedent for European approval fo Qinprezo."

— Matthew Andrews, Wells Fargo Securities (11/6/15)
more >

"Of most interest is when SNSS files the Qinprezo MAA in Europe."

— Matthew Andrews, Wells Fargo Securities (10/5/15)
more >

"SNSS ended Q2/15 with $39.6M in cash."

— Matthew Andrews, Wells Fargo Securities (7/31/15)
more >

"The EMA encouraged SNSS to submit an MAA in R/R AML >60 years."

— Matthew Andrews, Wells Fargo Securities (7/24/15)
more >

"FDA and EMA meetings could lead to submissions by SNSS in late summer."

— Matthew Andrews, Wells Fargo Securities (6/12/15)
more >

"An overall survival trend favors SNSS' vosaroxin plus cytarabine."

— Matthew Andrews, Wells Fargo Securities (5/14/15)
more >

"SNSS' cash on hand at March 31, 2015 was $39.8M."

— Matthew Andrews, Wells Fargo Securities (5/6/15)
more >

"SNSS has made progress in a dialog with the FDA related to Qinprezo."

— Matthew Andrews, Wells Fargo Securities (3/12/15)
more >



Due to permission requirements, not all quotes are shown.